UBS/CALL/ROCHE GS/300.004/0.025/19.12.25 Share Price

Warrant

GROGDU

CH1177821415

Market Closed - Swiss Exchange 08:45:00 01/07/2024 pm IST
0.174 CHF 0.00% Intraday chart for UBS/CALL/ROCHE GS/300.004/0.025/19.12.25
1 month+51.30%
3 months+53.98%
Date Price Change
01/24/01 0.174 0.00%
28/24/28 0.174 -3.87%
26/24/26 0.181 -8.12%
25/24/25 0.197 -1.50%
24/24/24 0.2 +3.63%

Delayed Quote Swiss Exchange

Last update July 01, 2024 at 08:45 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
GROGDU
ISINCH1177821415
Date issued 20/06/2022
Strike 300 CHF
Maturity 19/12/2025 (536 Days)
Parity 40 : 1
Emission price 1.11 CHF
Emission volume N/A
Settlement Por entregas
Currency CHF

Technical Indicators

Highest since issue 1.443 CHF
Lowest since issue 0.093 CHF
Delta0.22x
Omega 8.200
Premium22.55x
Gearing37.14x
Moneyness 0.8343
Difference Strike 49.9 CHF
Difference Strike %+16.63%
Spread 0.009 CHF
Spread %5.20%
Theoretical value 0.1685
Implied Volatility 19.42 %
Total Loss Probability 84.09 %
Intrinsic value 0.000000
Present value 0.1685
Break even 306.74 CHF
Theta-0x
Vega0.02x
Rho0.02x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus
  1. Stock Market
  2. Warrants
  3. GROGDU Warrant